期刊文献+

原发肝淀粉样变性合并肝小静脉闭塞综合征一例

原文传递
导出
摘要 患者男,41岁,因间断双下肢水肿1个月于2013年5月18日入院.患者入院前1个月无明显诱因出现双下肢凹陷性水肿,劳累后加重,伴乏力、腹胀,无发热、恶心、胸闷、尿黄、血尿等症状,于当地诊所输液治疗(具体用药不详),自觉水肿减轻.于当地医院查ALT 69 U/L,AST 40 U/L,ALP275 U/L,GGT 933 U/L,白蛋白27.3 g/L;尿蛋白(+++);AFP 6.32 μg/L.超声检查示:左肾重度积水,左侧输尿管扩张,右肾体积大并实质弥漫性回声改变;肝大并实质弥漫性回声改变,肝右叶低回声结节,胆囊炎性改变.上腹部CT示肝肿大,不除外布-加综合征,静脉期及延迟期肝右叶低密度病变,考虑局灶性浸润或炎性病变;胆囊炎并胆囊积液;左肾积水.既往体健,无毒物及药物接触史,无家族遗传病史及传染病史.入院体格检查:体温37.0℃,脉搏84次/min,呼吸21次/min,血压134/86 mmHg (1 mmHg=0.133 kPa),神志清,巩膜无黄染,无肝掌及蜘蛛痣,全身浅表淋巴结未触及,心肺未见明显异常,腹平软,全腹无压痛及反跳痛,肝肋下约10 cm,剑突下约5 cm,质地硬,轻度压痛,移动性浊音阴性,双下肢轻度凹陷性水肿.
出处 《中华消化杂志》 CAS CSCD 北大核心 2014年第8期561-562,共2页 Chinese Journal of Digestion
  • 相关文献

参考文献7

  • 1Perfetto F,Moggi-Pignone A,Livi R,et al.Systemic amyloidosis:a challenge for the rheumatologist[J].Nat Rev Rheumatol,2010,6(7):417-429.
  • 2Ikeda S.Diagnosis and treatment in systemic amyloidosis[J].Rinsho lByori,2008,56(2):121-129.
  • 3Gioeva Z,Kieninger B,R(o)cken C.Amyloidosis in liver biopsies[J].Pathologe,2009,30(3):240-245.
  • 4Cefalo MG,Maurizi P,Arlotta A,et al.Hepatic veno-occlusive disease:a chemotherapy-related toxicity in children with malignancies[J].Paediatr Drugs,2010,12(5):277-284.
  • 5孙玉岭,马秀现,许培钦.17例肝小静脉闭塞病患者的诊断和治疗[J].中华肝脏病杂志,2010,18(7):523-526. 被引量:7
  • 6Richardson PG,Murakami C,Jin Z,et al.Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure:response without significant toxicity in a high-risk population and factors predictive of outcome[J].Blood,2002,100(13):4337-4343.
  • 7刘嘉,张曦,陈幸华,孔佩艳,王庆余,高蕾,张诚,张颖,李云龙,曾韫璟.中西医结合预防造血干细胞移植后肝静脉闭塞病的临床观察[J].中国中西医结合杂志,2010,30(10):1049-1051. 被引量:4

二级参考文献23

  • 1宋朝阳,李玉华,郭坤元,吴秉毅.低分子肝素与前列腺素E_1脂微球联合应用预防异基因外周血干细胞移植后肝静脉闭塞病[J].第一军医大学学报,2003,23(5):494-494. 被引量:3
  • 2王强,鲁重美,温小恒.肝小静脉闭塞病[J].临床消化病杂志,2006,18(6):379-382. 被引量:11
  • 3Simon M,Hahn T,Ford LA,et al.Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation:possible beneficial use of low molecular weight heparin.Bone Marrow Transplant,2001,27:627-633.
  • 4Coppell JA,Brown SA,Perry DJ.Veno-occlusive disease:cytokines,genetics,and haemostasis.Blood Rev,2003,17:63-70.
  • 5Prakash AS,Pereira TN,Reilly PE,et al.Pyrrolizidine alkaloids in human diet.Mutat Res.1999,443:53-67.
  • 6DeLeve LD,Shulman HM,McDonald GB.Toxic injury to hepatic sinusoids:sinusoidal obstruction syndrome (veno-occlusive disease).Semin Liver Dis,2002,22:27-42.
  • 7Jones RJ,Lee KS,Beschorner WE,et al.Venoocclusive disease of the liver following bone marrow transplantation.Transplantation,1987,44:778-783.
  • 8Richardson PG,Murakami C,Jin Z,et al.Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure:response without significant toxicity in a high-risk population and factors predictive of outcome.Blood,2002,100:4337-4343.
  • 9Bulley SR,Strahm B,Doyle J,et al.Defibrotide for the treatment of hepatic veno-occlusive disease in children.Pediatr Blood Cancer,2007,48:700-704.
  • 10Komblum N,Ayyanar K,Benimetskaya L,et al.Defibrotide,a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease:clinical outcomes and potential mechanisms of action.Oligonucleotides,2006,16:105-114.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部